Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism

Abstract

(2016) Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism, Pharmaceutical Biology, 54:12, 2886-2894, DOI: 10.1080/13880209.2016 Context: Losartan and berberine (BBR) are often simultaneously used for the treatment of senile diabetic nephropathy in clinics. However, the potential herb-drug interaction between losartan and BBR is unknown. Objective: This study investigates the influence of BBR on the pharmacokinetics of losartan and EXP3174, and investigates the effects of BBR on the metabolic stability of losartan. Materials and methods: The pharmacokinetic profiles losartan and EXP3174 of orally administered losartan (10 mg/kg) with and without pretreatment with BBR (20 mg/kg) within 24 h were determined in Sprague-Dawley rats. The inhibitory effects of BBR on the metabolic stability of losartan were investigated using rat liver microsomes. Results: The C max (1.26 ± 0.37 versus 1.96 ± 0.45 mg/L) and the AUC (0-t) (8.25 ± 0.89 versus 12.70 ± 1.42 mg h/L) of losartan were significantly (p < 0.05) increased by BBR compared to the control, while the C max (0.97 ± 0.15 versus 0.77 ± 0.06 mg/L) of EXP3174 was significantly decreased compared to the control (p < 0.05). The T max of losartan was prolonged from 0.41 ± 0.12 to 0.52 ± 0.18 h, but the difference was not significant. However, the T max of EXP3174 was decreased significantly (p < 0.05) from 8.14 ± 0.36 to 3.33 ± 0.28 h. The metabolic stability of losartan was increased from 37.4 to 59.6 min. Discussion and conclusion: We infer that BBR might increase the plasma concentration of losartan and decrease the concentration of EXP3174 through inhibiting the activity of CYP3A4 or CYP2C9. ARTICLE HISTORY

Effects of diclofenac on the pharmacokinetics of celastrol in rats and its transport

“…To evaluate the effects of diclofenac on the pharmacokinetics of celastrol, the rats were divided into two groups of six animals (statistical significance) each as previously reported (Li et al. 2016 ; Wang et al. 2016 ).…”

The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism

“…Rat liver microsomes were used to determine the phase I metabolic stability of sorafenib. The assay conditions and reaction mixtures were similar as reported previously with minor modification (Qi et al 2013;Li et al 2016). In brief, except for NADPH-generating system (10 mM G-6-P, 1 mM NADP þ , 4 mM magnesium chloride, 1 unit/mL of G-6-PDH), 10 lL rat liver microsome (20 mg/mL), 4 lL sorafenib solution (100 lM) and 366 lL PBS buffer (0.1 M, pH 7.4) were added to the centrifuge tubes on ice.…”

Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats

“… 2015 ; Li et al. 2016 ). Recent studies show that berberine can be used for controlling arrhythmia, lowering blood lipid, lowering blood pressure and reducing blood sugar in clinical studies (Lei et al.…”